Special Issue

Molecular Mechanisms of Action of Natural Products in Alleviating Allergic Disease Symptoms

Message from the Guest Editor

According to the WHO, chronic inflammation and its associated diseases pose serious challenges to the health of the world in the near future. This realization has led to increased efforts to explore new therapeutic approaches against inflammatory diseases. Various synthetic drugs have been used to control and treat inflammatory diseases, with varying results. However, there certain health concerns can arise when these synthetic drugs are taken for a long period of time. Therefore, safe and cost-effective therapeutic alternatives need to be developed to combat this threat in a sustainable manner. Natural ingredients have been used for many millennia to treat various human ailments. Nearly 35% of the drugs and their derivatives approved by the FDA between 1981 and 2010 were derived from natural sources. The aim of this Special Issue is to investigate the anti-inflammatory and anti-allergic potential of new natural products in alleviating symptoms of allergic diseases or combating their mechanisms of action.

Guest Editor

Dr. Natalia Karolina Galińska

Faculty of Biology and Biotechnology, University of Warmia and Mazury, 10-719 Olsztyn, Poland

Deadline for manuscript submissions

closed (30 September 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/164746

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

